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Abstract:
Background: Survivors of paediatric brain cancer and/or cranial radiotherapy (CRT) are at an increased risk of
developing serious comorbidities. Established risk factors for chronic disease include central obesity, endothe-
lial abnormalities and diminished fitness.
Objectives: Here we characterised anthropometry, body composition, bone mineral density (BMD), heart rate
(HR), blood pressure (BP), endothelial function, muscular strength and endurance and aerobic fitness in ado-
lescent and young adult (AYA) survivors.
Methods: Twenty survivors (10 male, 10 female; 20 ± 2 years) were compared with 19 matched controls. Mus-
cular strength was assessed using three repetition maximum tests, while muscular endurance was determined
as number of repetitions performed per minute. Peak oxygen uptake (VO2 peak) was assessed on a treadmill
using amodified chronotropic protocol. Anthropometric measurements, HR and BPwere taken using standard
clinical protocols, while body composition and BMDwere determined using dual X-ray absorptiometry (DXA).
Endothelial function was measured using the flow mediated dilation technique.
Results: Survivors demonstrated deficits inmuscular strength (latissimus dorsi pull-down, p = 0.020; bicep curl,
p = 0.009), muscular endurance (squats, p = 0.012; sit-ups, p = 0.030; push-ups, p = 0.013), minute ventilation at
peak exericse (p = 0.002) and VO2peak (L/min, p = 0.002; mL/kg/min, p = 0.008; mL/kg LBM/min, p = 0.010).
Additionally, survivors had greater waist-to-hip ratios (p = 0.032), resting HR (p = 0.048) and higher percentage
of total body (p = 0.017), central (p = 0.009) and peripheral (p = 0.032) fat. Lean body mass (p = 0.004) and BMD
(p = 0.005) were lower in the survivor group.
Conclusion: AYA survivors of paediatric brain cancer and/or CRT exhibit altered body composition, increased
restingHR and reduced BMD,muscular strength, muscular endurance and cardiorespiratory fitness compared
to controls.
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Introduction
In recent years, overall survival rates for paediatric cancers have increased. Unfortunately, it is estimated that
62% of the paediatric cancer survivors develop at least one chronic health conditionwithin 17 years of diagnosis
[1]. Long-term survivors of paediatric brain cancer and/or cranial radiotherapy (CRT) who undergo invasive
and intensive treatment have a higher incidence of adverse effects [2], [3], [4], [5]. Further, as a consequence of
the cancer itself, survivors may develop a range of physical performance limitations that decrease quality of life
and increase overall risk of developing comorbidities [2], [5]. Numerous studies have documented such predis-
positions in adolescent and young adult (AYA) survivors of paediatric brain cancer and/or CRT, indicating a
LouiseH.Naylor is the corresponding author.
©2017Walter de Gruyter GmbH, Berlin/Boston.
1
Brought to you by | University of Gothenburg
Authenticated
Download Date | 10/2/17 5:25 PM
A
ut
om
at
ic
al
ly
ge
ne
ra
te
d
ro
ug
h
PD
F
by
Pr
oo
fC
he
ck
fr
om
R
iv
er
Va
lle
y
Te
ch
no
lo
gi
es
Lt
d
Long et al. DEGRUYTER
considerable increase in disease risk and all-cause mortality within this population [2], [5], [6], [7], [8], [9], [10],
[11]. However, many of these studies have relied upon self-report data and field-based estimations to charac-
terise these deficits. As such, research containing accurate and reproducible measures of body composition,
vascular health and functional fitness in this population are scarce [4], [6]. Here, we utilise standardised and
well-recognised protocols to define cardiorespiratory fitness, muscular strength and endurance, anthropome-
try, heart rate (HR) and blood pressure (BP), endothelial function, body composition and bone mineral density
(BMD) in a population of long-term paediatric brain cancer and/or CRT survivors once they have reached ado-
lescence or early adulthood. This information could aid the development of future interventions to ameliorate
these risk-factors and prevent chronic disease in this population.
Materials andmethods
Participants
Twenty-one long-term (>5 years) AYA (15–23 years) survivors of paediatric brain cancer and/or CRT were re-
cruited from the PrincessMargaret Hospital (Western Australia) oncology database. One survivor dropped out
of the study after initial recruitment due to personal reasons. Hence, 20 survivors (10 male, 10 female) partici-
pated in this study. Nineteen (9 male, 10 female) healthy control participants of similar age were recruited from
the community. It was a requirement that all participants were ambulatory and capable of participating in exer-
cise. Survivorswith growth hormone deficiency (GHD) had ceasedGH replacement 6months prior to enrolling
in the study as therapy was only available until skeletal maturity. Exclusion criteria included pregnancy, cur-
rent inflammatory or malignant disease/s, and previous diagnoses of cardiovascular disease or dysfunction of
clinical importance. Survivors with neurological and/or physical deficits were screened prior to recruitment by
study doctors to determine exercise and participation capability. All participants were informed of the details
and requirements of the study and provided written informed consent. Ethical approval was granted by the
University ofWestern Australia (UWA)Human Research Ethics Committee and the PrincessMargaret Hospital
Ethics Committee (HREC approval number, 2013059). All procedures performed were in accordance with the
1964 Helsinki declaration and its later amendments.
Experimental design
Participants were invited to complete a single 2-h testing session at the UWA School of Sport Science, Exer-
cise and Health. At this testing session anthropometry, body composition, BMD, HR, BP, endothelial function,
muscular strength, muscular endurance and cardiorespiratory fitness were assessed.
Heart rate, blood pressure and endothelial function
Participants fasted for 4 h preceding their appointment and rested supine for 20 min upon arrival to the lab-
oratory. During this time an electronic cuff (Dinamap Carescape V100, GE Healthcare, Chalfont St Giles, UK)
was used to measure HR, BP and mean arterial pressure (MAP) at 5-min intervals.
Conduit artery function was then assessed using the flow mediated dilation (FMD) technique defined by
Thijssen et al. [12]. A forearm cuff was placed distal to the olecranon process before the left brachial artery was
imaged using non-invasive, high-resolution ultrasound (Terason, t3200, Burlington, MA, USA). After 1 min of
recording brachial artery diameter, the cuff was inflated to 220 mm Hg for 5 min. Recordings of diameter and
blood flow resumed 30 s before cuff deflation and continued for another 3 min following release.
Anthropometry, body composition andbonemineral density
Bodymass, height, bodymass index (BMI), waist circumference, hip circumference and waist-to-hip ratio were
measured. Body mass was measured to the nearest 0.01 kg using an electronic scale (Sauter Model EB60, FSE
Scientific, Sydney, Australia). Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer
(Seca 216 Measuring Pole, Birmingham, UK). BMI was calculated as body mass divided by height in metres
squared (kg/m2). The World Health Organisation (WHO)’s criteria for BMI were used for classification pur-
poses [13]. Waist circumference was measured at the mid-level between the lateral T12 costal arch and the iliac
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crest, while hip circumferencewasmeasured at the level of the greater trochanters according to guidelines from
the American College of SportsMedicine (ACSM) [14].Waist-to-hip ratio was calculated as waist circumference
divided by hip circumference.
Total and regional body composition and BMDwere assessed using dual X-ray absorptiometry (DXA; Lunar
Prodigy, GEMedical Systems,Madison,WI, USA). Paediatric software and reference valueswere used for those
participants aged 15–18 years. Total body fat, central and peripheral fat were presented in kg and as percentages
of tissue mass. Central adiposity was defined as the area encompassing the trunk and android regions, while
peripheral adiposity was defined as the sum of the arms, legs and gynoid region. Total lean body mass (LBM)
was presented in kg and BMD was determined by dividing bone mineral content by bone area (g/cm2).
Muscular strength and endurance
Protocols for muscular strength and endurance testing were in accordance with ACSM guidelines [14].
Before evaluation, participants were guided through a 5–10 min warm-up consisting of static stretching
and familiarisation, consisting of several light intensity repetitions of the specific exercises being tested so that
correct technique could be achieved and full range of motion (ROM) of each exercise successfully adhered to.
Muscular strength in the upper bodywas assessed using standardised three repetitionmaximum (RM) tests
in which latissimus dorsi and biceps brachii strength was assessed using pull-down and unilateral curl exer-
cises. In these tests, participants were required to move the greatest resistance they could manage three times
through the full joint ROM in a controlled manner with good posture. To begin with, the average strength of
each participant was gauged through questioning. Maximum strength was then assessed by increasing weight
in 5–10 kg increments for latissimus dorsi pull-downs and 1–5 kg increments for bicep curls from an initial
weight of ∼50%–70% of predicted capacity. Repetition maximums were taken at the point before technique
was compromised or when participants indicated a maximal effort.
Latissimus dorsi pull-downs were performed in a seated position on a standard, weighted pulley machine.
A wide, over-hand grip was used to hold the bar, with one complete repetition performed when the bar could
be lowered to the level of the chin and back above the head in a controlled motion. Participants performed
bicep curls using dumbbell weights. Left and right arms were assessed individually, with one repetition taken
as full elbow extension beside the body to full elbow flexion next to the chest. Results for left and right arms
were combined and averaged for analysis.
Relativemuscular endurancewas assessed using standard 1-minmaximum tests inwhich participants were
required to complete as many repetitions of each exercise as possible in 1 min, with good form. Three of these
testswere conducted inwhich strength of the trunk, legs and chestwas assessed through the use of un-weighted
abdominal crunches, squats and push-ups.
Cardiorespiratoryfitness
Peak oxygen uptake (V̇O2 peak) was assessed on a treadmill using a modified chronotropic protocol designed
for clinical populations. Prior to commencing the test, resting heart rate (HR; Polar Electro Oy, Kempele, Fin-
land) and bloodpressure (BP; Bronze SeriesDS54DuraShockHandAneroid Sphygmomanometer,WelchAllyn,
Skaneateles Fall, NY, USA) were recorded. Each stage was 3-min in duration with participants encouraged to
continue until volitional exhaustion. At the end of each 3 min stage, HR, BP and ratings of perceived exertion
(RPE), based upon the Borg scale (6-20) [15] were recorded. Recovery HR and BP were also measured and
recorded 10 min after cessation of the exercise test.
During the assessment, participants breathed through a mouthpiece connected to a computerised gas anal-
ysis system. This system included a ventilometer (Universal ventilation meter, VacuMed, Ventura, CA, USA)
to calculate minute ventilation (V̇E) and respiratory exchange ratio (RER) at 15-s intervals, in addition to oxy-
gen and carbon dioxide analysers (Ametek Applied Electrochemistry S-3A/1 and CD-3A, AEI Technologies,
Pittsburgh, PA) to measure the percentage of oxygen and carbon dioxide in the expired air. Calibration of the
ventilometer was completed prior to each test and the analysers were calibrated prior to use and verified after
each test using a standard reference gas of known concentration. Values were recorded in absolute (L/min) and
relative (mL/kg/min) terms. Absolute V̇O2 peak was then converted into mL and divided by LBM for a true
representation of aerobic capacity.
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Statistical analyses
Data were analysed using SPSS (version 20.0, IBM, Armonk, NY, USA). All descriptive data was reported as
mean ± standard deviation (SD). Unpaired (independent samples) two-tailed Student’s t-tests were used to
analyse the differences in outcome measures between the two groups. Statistical significance was set at p ≤
0.05 for all analyses.
Results
Participant characteristics
The mean age for both the survivors and control participants was 20 ± 2 years. The mean time since last treat-
ment was 11.91 ± 4.60 years. At time of review, all participants had completed puberty based on menarchal
timing in females and self-identified Tanner stages in males. Additional characteristics of the survivor group
are presented in Table 1.
Table 1: Characteristics of the cancer survivor group.
Survivor (n = 20)
No. %
Age at first diagnosis
 <5 years 13 65
 6–10 years 5 25
 11–15 years 2 10
Age at first exposure
 N/A 6 30
 <5 years 8 40
 6–10 years 4 20
 11–15 years 2 10
Age at last exposure
 N/A 6 30
 <5 years 5 25
 6–10 years 4 20
 11–15 years 5 25
Underlying diagnosis
 Brain cancer 13 65
  Tumour type
   Craniopharyngioma 1 5
   Glioma 10 50
   Medulloblastoma 1 5
   Teratoma 1 5
  Tumour location
   Brain stem 1 5
   Cerebellum 1 5
   Frontal lobe 2 10
   Optic pathway 2 10
   Posterior fossa 2 10
   Subependymal zone 1 5
   Supracellar cistern 1 5
   Temporal lobe 2 10
   Tempero-parietal region 1 5
 Leukaemia 6 30
  ALL 5 25
  MML 1 5
 Other
  Undifferentiated
rhabdomyosarcoma of the right
petrous temporal bone
1 5
Treatment
 Surgery 6 30
4
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 Surgery and chemotherapy 1 5
 Surgery and XRT 2 10
 Chemotherapy and XRT 2 10
 Surgery, chemotherapy and XRT 5 25
 Chemotherapy, XRT and HSCT 4 20
Treatment details
 XRT
  Dosage
   6–24 Gy 6 30
   50–56 Gy 7 35
  Location
   Cranial 9 45
   Spinal 2 10
   Total body 4 20
 Chemotherapy
  Agents
   Alkylating agents 9 45
   Anthracyclines 6 30
   Vinca alkaloids 9 45
Other characteristics
  Growth hormone deficiencya 8 40
ALL, acute lymphoblastic leukaemia; HSCT, haematopoietic stem cell transplant; MML, myelo monocytic leukaemia; XRT, radiotherapy.
aParticipants had not received hormonal supplements for the 6 months preceding the study.
Survivor data was further investigated for trends based on treatment (Appendix Table 5) and hormone sta-
tus (Appendix Table 6). Survivors who received surgery and/or chemotherapy recorded higher maximal HR in
the V̇O2 peak assessment than those who received radiotherapy. Survivors with GHD and thyroid stimulating
hormone (TSH) deficiencywere significantly shorter than their counterparts and had lower hip circumferences,
LBM and absolute V̇O2 peak. There were no other significant differences observed between treatment or hor-
mone groups.
Heart rate, blood pressure and endothelial function
All vascular data is presented in Table 2.
Table 2: Heart rate, blood pressure and endothelial function data for the cancer survivor group and the control group.
Survivor (n = 20) Control (n = 19)
Mean SD Mean SD p-Value
Heart rate and blood pressure
 Systolic blood pressure, mm Hg 117 17 120 12 0.637
 Diastolic blood pressure, mm Hg 69 11 65 4 0.146
 Mean arterial pressure, mm Hg 88 14 86 6 0.583
 Heart rate, bpm 76 14 66 14 0.048a
Endothelial function
 Baseline diameter, cm 0.31 0.07 0.35 0.07 0.111
 Peak diameter, cm 0.34 0.07 0.38 0.07 0.079
 Delta diameter, cm 0.05 0.07 0.03 0.02 0.475
 Delta percent, % 10.35 3.84 10.18 5.47 0.918
 Time to peak, s 53.15 25.60 60.30 30.46 0.457
aDenotes statistical significance (p ≤ 0.05).
Cancer survivors had significantly higher resting HR compared to control participants. There were no other
significant differences between groups in BP or endothelial function data.
Anthropometry, body composition andbonemineral density
As a group, cancer survivors were shorter than the control participants and had higher waist-to-hip ratios
(Table 3). According to the WHO criteria for BMI [13], 15.8% of individuals in the survivor group were un-
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derweight (BMI < 18.5 kg/m2), 36.8% were within the normal weight range (BMI 18.5–24.99 kg/m2), 36.8%
were overweight (BMI 25.0–29.99 kg/m2) and 10.5% were obese (BMI > 30 kg/m2). In comparison, no controls
were underweight, 57.9% were normal weight, 36.8% were overweight and 5.3% were obese. There were no
significant differences between groups in all other anthropometric measures (Table 3).
Table 3: Anthropometric, body composition and bone mineral density data for the cancer survivor group and the control
group.
Survivor (n = 20) Control (n = 19)
Mean SD Mean SD p-Value
Anthropometry
 Height, cm 164.1 12.9 176.3 8.1 0.001a
  Stature-for-age z score
   Females (15–18) –3 –1
   Females (18+) –0.5 1.1 1.2 1.2 0.009a
   Males (15–18) –1.1 1.8 0.6 0.9 0.121
   Males (18+) –0.7 1.6 0.3 0.8 0.243
  Body mass, kg 66.55 22.50 74.69 14.83 0.193
  Body mass index, kg/m2 24.5 7.0 23.8 3.5 0.714
  Waist circumference, cm 79.4 15.2 76.7 10.4 0.523
  Hip circumference, cm 96.0 17.4 99.1 6.1 0.461
  Waist:hip ratio 0.83 0.07 0.77 0.08 0.032a
Body composition
  Total fat mass, kg 23.62 13.41 19.69 9.90 0.307
  Central fat mass, kg 14.20 9.33 10.60 6.36 0.171
  Peripheral fat mass, kg 15.26 7.74 14.22 6.72 0.659
  Total percent fat, % 36.08 9.82 27.53 11.52 0.017a
  Central percent fat, % 37.50 9.79 27.98 11.81 0.009a
  Peripheral percent fat, % 39.09 10.57 30.62 13.12 0.032a
  Total lean body mass, kg 39.45 11.74 51.58 12.96 0.004a
Bone mineral density
 Total bone mineral density, g/cm 1.13 0.11 1.23 0.11 0.005a
  z score
   Females (15–18) –2.0 0.1
   Females (18+) –0.6 1.7 0.5 0.8 0.121
   Males (15–18) –0.2 1.1 0.8 1.5 0.329
   Males (18+) 0.2 1.1 1.4 0.8 0.070
aDenotes statistical significance (p ≤ 0.05).
With regards to DXAmeasurements, total body, central and peripheral fat mass was not significantly differ-
ent between groups; however, percentage values for each measure were comparatively higher in the survivor
cohort. Further, reductions in total LBM and total BMD were observed in this group (Table 3).
Muscular strength and endurance
Cancer survivors had reduced measures of muscular strength and endurance when compared with controls
(Table 4).
Table 4:Muscular strength, muscular endurance and aerobic capacity data for the cancer survivor group and the control
group.
Survivor (n = 20) Control (n = 19)
Mean SD Mean SD p-Value
Muscular strength, kg
 Latissimus dorsi pull down 42 17 58 23 0.020a
 Bicep curl 8 3 12 6 0.009a
Muscular endurance (60 s)
 Squats 32 15 43 11 0.012a
 Sit-ups 26 9 34 11 0.030a
6
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 Push-ups 24 11 38 20 0.013a
Aerobic capacity
 Rating perceived exertion 17 3 18 2 0.102
 Maximal heart rate, bpm 182 13 188 10 0.165
 Minute ventilation, L/min 66.59 28.90 94.09 21.64 0.002a
 Respiratory exchange ratio 1.05 0.28 1.06 0.07 0.930
 V̇O2 peak, L/min 2.4 1.05 3.49 0.97 0.002
a
 V̇O2 peak, mL/kg/min 35.84 13.53 46.61 9.44 0.008
a
 V̇O2 peak, mL/kg LBM/min 57.42 13.18 67.29 6.29 0.010
a
LBM, lean body mass.
aDenotes statistical significance (p ≤ 0.05).
Peak oxygenuptake
All aerobic capacity data is presented in Table 4. Cancer survivors recorded lower absolute and relative
V̇O2 peak values compared with control participants. Significant reductions were observed when V̇O2 peak
was calculated based on LBM. Cancer survivors also recorded lower values for  at peak exercise.  There were
no significant differences between cancer survivors and control participants in measures of maximal RPE, RER
and maximal HR recorded during the assessment(s).
Discussion
This study utilised standardised and well-recognised protocols to characterise physical fitness and body com-
position in a cohort of adolescent and young adult survivors of paediatric brain cancer and/or CRT. When
compared to healthy controls, survivors demonstrated poorer muscular performance and cardiorespiratory
fitness, coupled with reduced LBM and BMD. Further, increased percentages of total body, central and pe-
ripheral fat were observed in the survivor cohort, as well as greater waist-to-hip ratios and resting HR. Finally,
survivors were significantly shorter in stature than their counterparts.
Muscular strength, muscular endurance and aerobic capacity were assessed using optimal exercise physi-
ology protocols, facilitating comparison with established reference values. Survivor ratings for these measure-
ments were poor when compared to age-appropriate normative data. In fact, values for V̇O2 peak were equiva-
lent to those expected formale and female cohorts aged 60–69 years and 50–59 years, respectively [14]. Similarly,
abdominal endurance scores for the survivors corresponded to values typical for individuals between the third
and fifth decades of life [16]. These results are consistent with those reported by Ness et al. [5] who found esti-
mates of V̇O2 peak and muscular strength for adult survivors of paediatric brain cancer to be within the range
expected for a cohort of individuals aged 60–69 years. Likewise, Wolfe et al. [11] reported significantly reduced
estimates of treadmill maximal oxygen uptake for survivors of posterior fossa tumours when compared to
similarly-aged, healthy control participants. This reinforces the notion that AYA survivors of paediatric brain
cancer and/or CRT are at an enhanced risk of physical impairment and early-onset chronic disease typically
associated with older-age [5], [17]. Moreover, aerobic insufficiency andmuscular weakness are both causes and
consequences of physical inactivity [18], [19]. This may create a deconditioning cycle that eventually restricts
independence [20], [21] and further predisposes this cohort to inactivity-induced disease [18], [19], [22], [23],
[24], [25], [26], [27].
Consistent with our muscular strength and endurance results, LBM was reduced in the survivor cohort –
particularly in those with GHD and TSH deficiency. These findings are important as previously reported data
on LBM in this population has failed to reach significance [28], although studies in other paediatric cancer sur-
vivor groups have corroborated our findings [10], [21], [28]. Our results may reflect the cancer-related fatigue,
muscular catabolism and overall deconditioning that occurs in paediatric brain cancer and/or CRT survivors
both during and after treatment [20], [21], [27].
Obesity is one of the most commonly reported side-effects of childhood cancer treatment [21], [24], [25],
[27], [29], [30]. Survivors of paediatric brain cancer and/or CRT may develop obesity as a result of treatment
consequences – such as GHD or hypothalamic damage – or imbalances between energy consumption and en-
ergy expenditure [3], [6], [7]. In this study, survivors had comparatively higher measurements of total body fat
and demonstrated both peripheral and central adiposity. These findings parallel with those found by Heikens
et al. [6] who reported increased waist-to-hip ratios in long-term survivors of paediatric brain cancer and Stein-
berger et al. [28] who observed abdominal adiposity in survivors of central nervous system tumours. This is of
7
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particular concern given that accumulation of central adiposity is a major cardio-metabolic risk factor for other
obesity-related diseases including insulin resistance, dyslipidaemia and hypertension [7], [9].
Another commonly reported side-effect of paediatric cancer treatment that was reflected in our results is
short stature [31], [32]. As parental heightswere not available, wewere not able to determine if therewas a famil-
ial contribution to the shorter stature of the survivor group. However, additional hormone deficiency is known
to negatively correlate with final height [33] which was reflected in the stature differences between the GHD
and TSH deficient group when compared to those with normal pituitary function. Further, treatment induced
GHD and gonadal failure have been reported to negatively influence bone metabolism andmineral acquisition
resulting in short stature and reduced BMD in this population [34], [35]. This is concomitant with our BMD
results and highlights the risk of fracture and subsequent osteopenia and osteoporosis in these survivors [36],
[37].
Limitations of our study include the small sample size and heterogeneous subject group. We were also un-
able to match the control participants for height and BMI. In order to account for these discrepancies, matches
occurred based on age and gender and V̇O2 peak data was analysed in relative terms and by LBM. Secondly,
while all of our participants were ambulatory, it is possible that potential treatment-induced balance and coor-
dination disturbances may have influenced treadmill performance and prevented the survivors from attaining
their true V̇O2 peak. It is important to note that cycle ergometry was considered for assessing V̇O2 peak in this
study but was deemed inappropriate due to some participants suffering pathologies that induced pain upon
seated movement and/or reduced limb range of motion. However, both of our cohorts recorded similar RPE,
RER and maximal HR values using the treadmill protocol, suggesting that physiological intensity and aerobic
effort were equal despite potential motor limitations in the survivor cohort. Whilst participants were asked
to identify their tanner stage and timing of menstruation, pubertal examination was not performed as it was
deemed too invasive for the purposes of this study. Historical details relating to timing of maximal growth
velocity were not available. It is possible that pubertal timing in this cohort may affect interpretation of our
BMD and strength data. Finally, while there were no stature differences in this study between those survivors
who received irradiation and those who did not, we did not have measures of sitting height to confirmwhether
there was an impact on spinal growth.
In summary, AYA survivors of paediatric brain cancer and/or CRT have significantly decreased functional
fitness, abnormal body composition and reduced BMD. These limitations not only have the potential to inhibit
performance of everyday activities but considerably increase the risk of chronic disease and all-cause mortal-
ity within this population. Therefore, it is important to consider the inclusion of physical fitness, function and
profile testing into the regular monitoring of survivors. As the testing protocols used in this study were time-
efficient, well tolerated by participants and modifiable based on ability, they are highly appropriate for use in a
clinical setting. The results of our study raise the question as to what extent implementation of exercise would
ameliorate further decline in physical fitness in a population of paediatric brain cancer and/or CRT survivors.
Specifically, determination of themost beneficial trainingmodality (e.g. resistance training vs. aerobic training),
training objective (e.g. decreased sedentary time or improved physical fitness) and initiation time should occur
so future practice can involve the implementation of such programmes.
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Appendix
Table 5: Comparison data for cancer survivors who received surgery and/or chemotherapy and cancer survivors who
received radiotherapy only.
Surgery and/or chemotherapy
(n = 7)
Radiotherapy
(n = 13)
Mean SD Mean SD p-Value
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Heart rate and blood pressure
 Systolic blood pressure, mm Hg 121 9 116 20 0.571
 Diastolic blood pressure, mm Hg 69 6 69 13 0.911
 Mean arterial pressure, mm Hg 89 5 87 17 0.836
 Heart rate, bpm 76 10 75 16 0.905
Endothelial function
 Baseline diameter, cm 0.34 0.07 0.31 0.07 0.461
 Peak diameter, cm 0.37 0.06 0.34 0.07 0.402
 Delta diameter, cm 0.03 0.01 0.06 0.09 0.576
 Delta percent, % 10.19 4.69 9.78 3.08 0.836
 Time to peak, s 50.41 39.59 54.16 20.93 0.799
Anthropometry
 Height, cm 168.51 18.17 161.77 9.12 0.278
 Body mass, kg 66.96 18.87 66.33 24.99 0.955
 Body mass index, kg/m2 23.1 3.5 25.2 8.3 0.542
 Waist circumference, cm 75.6 10.0 81.6 17.6 0.421
 Hip circumference, cm 95.0 8.6 96.5 21.4 0.863
 Waist:hip ratio 0.79 0.07 0.85 0.07 0.133
Body composition
 Total fat mass, kg 20.91 8.06 25.08 15.68 0.521
 Central fat mass, kg 12.02 5.10 15.37 10.98 0.459
 Peripheral fat mass, kg 14.24 5.45 15.81 8.90 0.677
 Total percent fat, % 33.56 10.13 37.43 9.78 0.415
 Central percent fat, % 35.02 10.37 38.83 9.62 0.422
 Peripheral percent fat, % 36.95 11.44 40.24 10.36 0.522
 Total lean body mass, kg 42.96 15.54 37.57 9.30 0.341
Bone mineral density
 Total bone mineral density, g/cm 1.14 0.09 1.13 0.12 0.875
Muscular strength, kg
 Lateral pull downs 49 18 38 15 0.184
 Bicep curl 8 3 7 4 0.805
Muscular endurance (60 s)
 Squats 34 12 30 17 0.612
 Sit-ups 25 7 28 10 0.500
 Push-ups 26 11 23 12 0.628
Graded exercise test
 Rating perceived exertion 17 1 16 3 0.345
 Maximal heart rate, bpm 190 3 178 15 0.023a
 Minute ventilation, L/min 80.63 39.55 58.41 17.75 0.200
 Respiratory exchange ratio 1.01 0.06 1.08 0.35 0.634
 V̇O2 peak, L/min 2.96 1.51 2.06 0.56 0.209
 V̇O2 peak, mL/kg/min 43.99 13.66 31.40 11.75 0.064
 V̇O2 peak, mL/kg LBM/min 65.68 11.29 52.92 12.28 0.053
LBM, lean body mass.
aDenotes statistical significance (p ≤ 0.05).
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